Literature DB >> 9876313

Role of protein kinase C as a cellular mediator of ischemic preconditioning: a critical review.

B Z Simkhovich1, K Przyklenk, R A Kloner.   

Abstract

Protein kinase C (PKC) has been proposed as a primary cellular mediator of ischemic preconditioning. However, the role of PKC in eliciting cardioprotection remains controversial. In this review, we summarize the evidence for and against the 'PKC hypothesis' of preconditioning, discuss the important technical limitations currently hampering PKC research, and suggest new approaches (i.e. PKC isoform-specific biochemical assays combined with immunoblotting techniques) that might aid in the definite resolution of this issue.

Entities:  

Mesh：

Substances：

Year:  1998        PMID： 9876313     DOI： 10.1016/s0008-6363(98)00142-4

Source DB:  PubMed          Journal:  Cardiovasc Res        ISSN： 0008-6363            Impact factor:   10.787


  12 in total

Review 1.  Therapeutic potential of ischaemic preconditioning.

Authors:  R J Edwards; A T Saurin; R D Rakhit; M S Marber
Journal:  Br J Clin Pharmacol       Date:  2000-08       Impact factor: 4.335

2.  Exercise preconditioning provides early cardioprotection against exhaustive exercise in rats: potential involvement of protein kinase C delta translocation.

Authors:  Yu-Jun Shen; Shan-Shan Pan; Jun Ge; Zhe Hao
Journal:  Mol Cell Biochem       Date:  2012-05-31       Impact factor: 3.396

3.  Diazoxide acts more as a PKC-epsilon activator, and indirectly activates the mitochondrial K(ATP) channel conferring cardioprotection against hypoxic injury.

Authors:  M-Y Kim; M J Kim; I S Yoon; J H Ahn; S H Lee; E J Baik; C-H Moon; Y-S Jung
Journal:  Br J Pharmacol       Date:  2006-10-16       Impact factor: 8.739

4.  Molecular basis of protein kinase C-induced activation of ATP-sensitive potassium channels.

Authors:  P E Light; C Bladen; R J Winkfein; M P Walsh; R J French
Journal:  Proc Natl Acad Sci U S A       Date:  2000-08-01       Impact factor: 11.205

5.  Low molecular weight fibroblast growth factor-2 signals via protein kinase C and myofibrillar proteins to protect against postischemic cardiac dysfunction.

Authors:  Janet R Manning; Sarah O Perkins; Elizabeth A Sinclair; Xiaoqian Gao; Yu Zhang; Gilbert Newman; W Glen Pyle; Jo El J Schultz
Journal:  Am J Physiol Heart Circ Physiol       Date:  2013-03-11       Impact factor: 4.733

6.  Epsilon protein kinase C lengthens the quiescent period between spontaneous contractions in rat ventricular cardiac myocytes and trabecula.

Authors:  Mourad Ogbi; Christopher J Wingard; Safia Ogbi; John A Johnson
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2004-09-25       Impact factor: 3.000

7.  Protein kinase C-dependent activation of P44/42 mitogen-activated protein kinase and heat shock protein 70 in signal transduction during hepatocyte ischemic preconditioning.

Authors:  Yi Gao; Yu-Qiang Shan; Ming-Xin Pan; Yu Wang; Li-Jun Tang; Hao Li; Zhi Zhang
Journal:  World J Gastroenterol       Date:  2004-04-01       Impact factor: 5.742

8.  Preischemic infusion of alpha-human atrial natriuretic peptide elicits myoprotective effects against ischemia reperfusion in isolated rat hearts.

Authors:  Hirohisa Okawa; Hitoshi Horimoto; Shigetoshi Mieno; Yukiya Nomura; Masataka Yoshida; Sasaki Shinjiro
Journal:  Mol Cell Biochem       Date:  2003-06       Impact factor: 3.396

9.  Repetitive preischemic infusion of phosphodiesterase III inhibitor olprinone elicits cardioprotective effects in the failing heart after myocardial infarction.

Authors:  Yukiya Nomura; Hitoshi Horimoto; Shigetoshi Mieno; Ken-ichi Nakahara; Hirohisa Okawa; Masataka Yoshida; Sasaki Shinjiro
Journal:  Mol Cell Biochem       Date:  2003-06       Impact factor: 3.396

10.  Resistin, an adipocytokine, offers protection against acute myocardial infarction.

Authors:  Jinping Gao; Chu Chang Chua; Zhongyi Chen; Hong Wang; Xingshun Xu; Ronald C Hamdy; Julie R McMullen; Tetsuo Shioi; Seigo Izumo; Balvin H L Chua
Journal:  J Mol Cell Cardiol       Date:  2007-08-22       Impact factor: 5.000
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.